Background illustration for clinical trials search

Paid Clinical Trials Surprise

Discover 1,271 paid clinical trials in Surprise, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,271

Diagnosing Epilepsy To EffeCT Change

for

Epilepsy, Epilepsy (Treatment Refractory)

Location: Phoenix AZ, Irvine CA, Palo Alto CA, Houston TX,

Sponsor: Epiminder America, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07110337

Recruiting

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for

Mesothelioma, Non Small Cell Lung Cancer,

Location: Phoenix AZ, Lone Tree CO, San Antonio TX, Fort Worth TX,

Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT05245500

Phase1, Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

for

Advanced or Metastatic Solid Tumors

Location: Phoenix AZ, Scottsdale AZ, Denver CO, Aurora CO,

Sponsor: DynamiCure Biotechnology

Sex: All

Age: 18+

Code: NCT05785754

Phase1, Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

for

Cutaneous Melanoma, Stage II

Location: Phoenix AZ, Gilbert AZ, Irvine CA, Orange CA,

Sponsor: Melanoma and Skin Cancer Trials Limited

Sex: All

Age: 18+

Code: NCT03860883

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

for

Primary Immune Thrombocytopenia (ITP)

Location: Phoenix AZ, Oceanside CA, Los Angeles CA, Aurora CO,

Sponsor: argenx

Sex: All

Age: 18+

Code: NCT06544499

Phase3, Recruiting

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

for

Recurrent Pericarditis

Location: Phoenix AZ, La Jolla CA, Irvine CA, Los Angeles CA,

Sponsor: Cardiol Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06708299

Phase3, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Phoenix AZ, Tucson AZ, Las Vegas NV, Albuquerque NM,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

for

Solid Tumor, HNSCC, RCC, CRC

Location: Phoenix AZ, Scottsdale AZ, Rochester MN,

Sponsor: SparX Biotech(Jiangsu) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06259552

Phase1, Recruiting

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

for

cGVHD

Location: Phoenix AZ, Duarte CA, Los Angeles CA,

Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT05919511

Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

for

Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma

Location: Phoenix AZ, La Jolla CA, Irvine CA, Orange CA,

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All

Age: 18+

Code: NCT04031677

Phase3, Recruiting

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

for

Malignant Glioma

Location: Phoenix AZ, Jacksonville FL

Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05030298

Phase1, Recruiting

Blue Light Cystoscopy With Cysview® Registry

for

Bladder Cancer

Location: Phoenix AZ, Los Angeles CA, Palo Alto CA,

Sponsor: Photocure

Sex: All

Age: 18+

Code: NCT02660645

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for

Non-small Cell Lung Cancer (NSCLC)

Location: Phoenix AZ, Burbank CA, Grand Junction CO, Reno NV,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06170788

Phase3, Recruiting

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for

KRAS G12C Mutation, KRAS G12S Mutation,

Location: Phoenix AZ, Denver CO, Oklahoma City OK, San Antonio TX,

Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT06720987

Phase1, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Phoenix AZ, Tucson AZ, Las Vegas NV, Upland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Phoenix AZ, Tucson AZ, Las Vegas NV, Irvine CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for

Metastatic Renal Cell Carcinoma,

Location: Phoenix AZ, Kingman AZ, San Diego CA, Encinitas CA,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05327686

Phase2, Recruiting

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

for

Solid Tumors

Location: Pheonix AZ, Irving TX, Houston TX, Rochester MN,

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Sex: All

Age: 18 - 70+

Code: NCT06963281

Phase1, Recruiting

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for

Malignancy

Location: Phoenix AZ, Kingman AZ, Henderson NV, Las Vegas NV,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 0+

Code: NCT04242095

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for

Neoplasms

Location: Phoenix AZ, Gilbert AZ, La Jolla CA, Duarte CA,

Sponsor: Celgene

Sex: All

Age: 0+

Code: NCT03435796

Phase2, Phase3, Recruiting

Paid Clinical Trials Surprise

Filter results

Diagnosing Epilepsy To EffeCT Change

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Interested in new trials?

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Blue Light Cystoscopy With Cysview® Registry

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells